Medical Oncologist
HER2-positive breast cancer treatment
Herceptin vs Biosimilar Trastuzumab: — Are They Really the Same?
If you have been given a different brand of trastuzumab than the one your oncologist first named, or if cost is making it hard to continue treatment, this comparison explains what actually differs between Herceptin and its approved biosimilars — and what does not.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Same mechanism — Both target the HER2 receptor. Regulatory approval requires demonstrated equivalence in how the molecule binds and what it does.
- Equivalence is required, not assumed — CDSCO, FDA, and EMA all require clinical trial data before a biosimilar is approved. Structural similarity alone is not enough.
- Neither reaches the brain well — Limited CNS penetration is a class-level limitation of trastuzumab — the same for originator and biosimilar alike.
- Cost is the main real-world difference — Completing your full recommended course matters more than which approved version you receive.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Approved biosimilar trastuzumab is considered highly similar to Herceptin in efficacy, safety, and mechanism of action. Regulatory agencies including the FDA, EMA, and CDSCO require clinical equivalence data before granting approval. The main practical difference for most patients is cost. The right question is which approved version your oncologist recommends and whether it is available at your centre.
How do Herceptin and biosimilar trastuzumab compare?
| Feature | Herceptin (originator) | Approved biosimilar trastuzumab |
|---|---|---|
| Mechanism of action | Binds the HER2 receptor, blocks growth signals, and triggers immune-mediated destruction of HER2-positive cells | Identical mechanism — regulatory approval requires demonstration of the same binding activity and downstream effects |
| Efficacy | Standard of care for HER2-positive breast and gastric cancers per NCCN and ESMO guidance | FDA, EMA, and CDSCO-approved biosimilars are determined to have no clinically meaningful difference in efficacy from the originator |
| Side effect profile | Cardiotoxicity risk, infusion reactions, fatigue — standard trastuzumab class effects; regular heart monitoring required | Same class effects and the same monitoring requirements; no additional or different side effects have been identified in approved biosimilars |
| CNS / brain activity | Limited — trastuzumab is a large molecule and does not cross the blood-brain barrier effectively | Same limitation — this is a class property of the drug, not a difference between originator and biosimilar |
| Cost in India (indicative, subject to change) | Higher — brand premium reflects originator development and trial costs | Substantially lower in most cases; the difference can be significant enough to affect whether a patient completes the full recommended course |
| Regulatory approval | Full approval across HER2-positive breast cancer and gastric cancer indications (FDA, EMA, CDSCO) | Each biosimilar requires its own separate approval — confirm which brand your centre uses and that it is CDSCO-approved for your cancer type |
| Who it typically suits | Patients continuing an established regimen; those in trials where the protocol specifies originator; where insurer requires it | New starts where an approved biosimilar is available; patients where cost is a barrier to completing the recommended course |
Does 'biosimilar' mean a cheaper copy that doesn't work as well?
A biosimilar is not a generic medicine. Generic drugs copy small, chemically identical molecules. Biologics like trastuzumab are large, complex proteins made in living cells, and no two manufacturing processes produce something molecularly identical — including different batches of the original Herceptin.
What regulatory approval means is that the biosimilar has been shown to be highly similar in structure and clinically equivalent in effect. CDSCO, the FDA, and EMA all require head-to-head clinical data before granting approval — the bar is not low.
If your oncologist offers you a CDSCO-approved biosimilar, they are not offering you a lesser treatment. They are offering a medicine that has cleared the same clinical standard at a lower price.
What do these terms actually mean?
- Biosimilar
- A medicine that is highly similar — but not molecularly identical — to an already-approved biologic, made by a different manufacturer after the originator's patent expires. Approved biosimilars have cleared clinical equivalence requirements set by the relevant regulatory body.
- Reference product (originator)
- The original approved biologic that other manufacturers compare their version against. For trastuzumab, the reference product is Herceptin. Every approved biosimilar must demonstrate equivalence to it.
- HER2-positive
- Your tumour makes too much of a protein called HER2, which drives cancer growth. Trastuzumab targets this protein specifically, which is why HER2 testing is required before the drug is prescribed to anyone.
- Extrapolation
- A biosimilar may be approved across all the indications of the reference product — including gastric cancer — without a separate trial for each indication, provided the mechanism is the same. Regulatory bodies determine when extrapolation is appropriate.
- Interchangeability
- Whether a pharmacist or hospital can substitute one brand of trastuzumab for another without a specific prescriber instruction. Rules vary by country and setting. Always confirm with your oncologist before a switch happens mid-treatment.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should you ask your oncologist before your next infusion?
- Which specific brand of trastuzumab does this centre use, and is it CDSCO-approved for my cancer type?
- Is there a reason to stay on the same brand throughout my treatment, or is switching mid-course acceptable?
- Will my heart monitoring schedule (ECHO or MUGA) stay the same regardless of which brand I receive?
- If I am starting treatment now, is your recommendation for originator or biosimilar based on a clinical or a practical reason?
- Am I enrolled in any clinical trial where the protocol specifies a particular brand?
Why does neither version reach the brain well?
Trastuzumab is a large antibody molecule. Large molecules do not cross the blood-brain barrier easily, which means that neither Herceptin nor any approved biosimilar is reliably effective at treating brain metastases on its own.
If brain metastases are a concern for you, your oncologist may add or switch to a treatment that penetrates the CNS more effectively. Certain small-molecule HER2-targeted drugs have better brain penetration than any form of trastuzumab.
This limitation is identical for originator and biosimilar. It is a property of the drug class, not a difference between the two versions.
Which version is right for you?
Your oncologist makes this decision based on what is available at your centre, what your insurance or reimbursement arrangement covers, and whether you are mid-treatment on an already-established regimen.
If cost is making it difficult to complete the recommended number of cycles, a CDSCO-approved biosimilar is a medically sound option. Completing your full course is what matters most.
If you are already several cycles into treatment on Herceptin, ask your oncologist whether switching mid-course is the right call before it happens. Most guidance supports switching between an originator and an approved biosimilar, but the decision should be made explicitly — not by administrative convenience.
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is it safe to switch from Herceptin to a biosimilar mid-treatment?
Most guidance from ESMO and regulatory bodies considers switching between originator Herceptin and an approved biosimilar to be acceptable. Several clinical programmes have studied switching and found no difference in outcomes or safety profiles. The decision should still be made by your oncologist, not by an administrative or supply decision — if a switch is planned, you should be told about it and have the opportunity to ask questions. If a switch happened without your knowledge, raise it with your team and ask for the reason.
How do I know if the biosimilar my centre uses is actually approved?
Ask your oncologist or the hospital pharmacy team for the specific brand name and ask them to confirm it carries CDSCO approval for your cancer type. CDSCO maintains a list of approved biosimilars and their indications. If your centre cannot confirm approval, that is a legitimate concern to raise. Ask your oncologist to note the specific brand in your treatment records — this also helps if you ever transfer care to another centre.
My doctor prescribed Herceptin but the centre gave me a different brand — is that acceptable?
This is worth raising with your team — not because the medicine is likely to differ in effect, but because you have a right to know what you are being given and why. Ask your oncologist to confirm that the version administered was a CDSCO-approved biosimilar and to explain the reason for the substitution. Most centres have a policy on brand substitution, and the conversation is entirely reasonable. Note the brand name given so you can track consistency across future cycles.
Does it matter if I receive different brands of trastuzumab across different cycles?
Using different approved brands across cycles is not automatically harmful, and regulatory guidance in several countries permits it. There is, however, a practical argument for consistency: it simplifies monitoring and reduces the chance of confusion if a side effect or infusion reaction occurs. Ask your oncologist what their preference is and whether your centre can maintain the same brand throughout your course. If a change is unavoidable, make sure it is noted in your records.
Can biosimilar trastuzumab be used for gastric cancer as well as breast cancer?
Yes — trastuzumab is approved for HER2-positive gastric and gastro-oesophageal junction cancers as well as breast cancer, and this indication generally extends to approved biosimilars through the extrapolation principle. Each biosimilar carries its own specific approval, so confirm with your oncologist and the treating team that the brand your centre uses is approved for your particular cancer type. Do not assume that approval for breast cancer automatically covers your diagnosis.
Is the cost saving on biosimilar trastuzumab significant in India?
The difference is substantial enough to affect whether some patients can complete their full recommended course — which is the more important outcome. Exact prices vary by centre, city, and procurement arrangement and change over time, so any figure quoted should be treated as indicative. Ask the billing or pharmacy team at your centre for a current cost estimate per cycle, and ask your oncologist whether the total number of planned cycles changes the calculation for you.